Archive for: November 2007

Doctors reading the results of a blood test widely used to screen for prostate cancer can be fooled into thinking obese men are disease free, researchers reported in The Journal of the American Medical Association. The test may yield falsely reassuring results because obese people have more blood in their bodies because of their girth, diluting the concentration of the protein doctors use to detect the presence of tumors, researchers said. The prostate gland produces a protein called prostate-s...

HealthDay - MONDAY, Nov. 26 (HealthDay News) -- More than a third of prostate cancer patients may receive treatments that are inappropriate because of problems they are already having with urinary, bowel or sexual function, a new study suggests.

HealthDay - TUESDAY, Nov. 20 (HealthDay News) -- In recent years, doctors have learned that they need to adjust the results of blood tests to properly diagnose prostate cancer in obese men, but now researchers think they know why.

HealthDay - WEDNESDAY, Nov. 14 (HealthDay News) -- A highly targeted biologic drug called cetuximab (Erbitux) is the first to extend the survival of patients with advanced colon cancer who have otherwise proved resistant to conventional chemotherapy, Canadian researchers confirmed.

HealthDay - TUESDAY, Nov. 13 (HealthDay News) -- In mice, a low-carbohydrate diet slowed prostate tumor growth, possibly because fewer carbohydrates leads to a drop in insulin production, U.S. researchers say.

HealthDay - MONDAY, Nov. 12 (HealthDay News) -- In another sign that too much weight spells health problems, new research suggests that fat men are twice as likely to die after being diagnosed with prostate cancer than men of normal weight.

HealthDay - MONDAY, Nov. 12 (HealthDay News) -- In another sign that too much weight spells health problems, new research suggests that fat men are twice as likely to die after being diagnosed with prostate cancer than men of normal weight.

HealthDay - WEDNESDAY, Nov. 7 (HealthDay News) -- In mice, an investigational agent called VN/14-1 proved effective in treating human prostate cancer, say researchers at the University of Maryland in Baltimore.

Reuters - Drugmaker Novacea Inc ended a late-stage trial of its prostate cancer drug Asentar, after a treatment arm containing the drug showed a higher death rate compared with the standard care, driving shares down more than 69 percent to a lifetime low.

HealthDay - FRIDAY, Nov. 2 (HealthDay News) -- Radiation seed implants, known as brachytherapy, are just as effective for treating prostate cancer in men 60 and younger as they are for older men, a new study finds.